Please login to the form below

trastuzumab

This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.

Ocrevus surge keeps Roche smiling in Q3

Meanwhile, breast cancer therapy Herceptin (trastuzumab) also continued its European decline thanks to biosimilar competition, failing 10%, but grew 2% to CHF 5.3bn overall and is once again Roche’s

Latest news

Roche preps new Kadcyla filings after phase 3 trial win

In the KATHERINE study, giving Kadcyla (ado-trastuzumab emtansine) to women with residual disease despite pre-surgery (neoadjuvant) therapy significantly reduced invasive disease-free survival or IDFS compared to Herceptin (trastuzumab), ... Meanwhile,
Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

The Japanese drugmaker’s has started recruiting patients into two pivotal trials of its ADC trastuzumab deruxtecan (DS-8201), one of which will pit the drug against Kadcyla (ado-trastuzumab emtansine) ... in HER2 positive, unresectable and/or
AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

The Institute had already rejected it in this setting in June, but looked again to see if the arrival biosimilars of Herceptin (trastuzumab) – which is administered with Perjeta – would help improve ... NICE already recommends Perjeta with
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar

Pfizer has gained European approval for its Herceptin (trastuzumab) biosimilar product, Trazimera.

More from news
Approximately 15 fully matching, plus 158 partially matching documents found.

Latest Intelligence

2016: The year when deal-makers took stock?

Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab).
Deal Watch October 2016

Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
Current development and marketing of biosimilar monoclonal antibodies in Latin America

7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.
An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.
Tough times for pharma in Portugal

In other cases there is a significant decrease in spending on drugs such as Roche's Herceptin (trastuzumab) for breast cancer, which the company explains through price reductions.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

AVEO's financial head joins ImmunoGen

cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Associate Editorial Director – Med Comms – London: Salary TBC

Events Manager – Med Comms – Surrey: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Medical Writers: Competitive Salary and Benefits

Senior Account Director development role to Business Director, H...: Excellent package

Account Director: Excellent benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Consumer Health Account Director: Circa £60, 000 Gym and More

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

New Business Director - PR: Competitive Salary and benefits

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Associate Director: £75, 000-90, 000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Associate Director, Market Access & HEOR – North-West: Negotiable

Senior Medical Writer: Great salary and benefits

Senior Medical Writer: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Project / Account Manager (Medical Education): Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical/ Scientific Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...